N-Nitroso Meglumine: The Nitrosamine Impurity Standard Every Pharma Lab Needs

 

In the rapidly evolving landscape of pharmaceutical quality control, few topics demand more attention than nitrosamine impurities. Among these, N-Nitroso Meglumine has emerged as a critical reference standard for laboratories working with meglumine-based drug products. Understanding this impurity — its origin, regulatory significance, and analytical applications — is essential for every pharmaceutical quality and regulatory team today.

For certified N-Nitroso Meglumine reference standards with comprehensive characterization data, SynZeal Research Pvt. Ltd. is a trusted supplier to pharmaceutical companies worldwide.

What Is N-Nitroso Meglumine?

N-Nitroso Meglumine is chemically identified as N-Methyl-N-((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)nitrous amide. It carries the CAS number 10356-92-0 and has the molecular formula C₇H₁₆N₂O₆ with a molecular weight of 224.21 g/mol.

It is the N-nitroso derivative of Meglumine — a widely used pharmaceutical excipient and amino sugar that serves as a solubilizing agent, salt-forming agent, and pH modifier in numerous injectable and oral drug formulations. Because Meglumine contains a secondary amine in its structure, it becomes susceptible to nitrosation under specific chemical conditions, giving rise to this impurity.

N-Nitroso Meglumine belongs to the broader class of N-nitrosamine impurities — compounds characterised by a nitroso group bonded to an amine. This class of compounds has been under intense regulatory scrutiny globally since 2018, when nitrosamine contamination was first detected in widely used cardiovascular medicines.

How Does N-Nitroso Meglumine Form?

The formation of N-Nitroso Meglumine follows the well-established nitrosation pathway. When Meglumine — as an excipient or active ingredient component — comes into contact with a nitrosating agent such as sodium nitrite under acidic conditions, the secondary amine group undergoes nitrosation to produce this impurity.

Practically, this means N-Nitroso Meglumine can form during:

  • Manufacturing of contrast agents such as iopamidol and iomeprol that use meglumine salts

  • Production of injectable formulations containing meglumine-based drug substances

  • Processing of drug substances or intermediates where meglumine is used as a solubilizing agent

  • Storage of meglumine-containing formulations, particularly under conditions that favour nitrosation

  • R&D development of new meglumine-based complex formulations

Even trace levels of nitrosating agents — whether from raw materials, processing environments, or packaging — can initiate impurity formation. This makes proactive monitoring and robust analytical testing essential for any manufacturer working with meglumine.

Why Is N-Nitroso Meglumine a Regulatory Priority?

N-nitrosamine impurities, including N-Nitroso Meglumine, are classified as potential human carcinogens. Regulatory agencies worldwide have responded with comprehensive guidance frameworks requiring pharmaceutical manufacturers to assess, detect, and control nitrosamine levels in their products.

The key regulatory drivers include:

  • US FDA — Has issued guidance requiring manufacturers to conduct risk assessments for nitrosamine impurities across all drug products and implement appropriate controls

  • EMA (European Medicines Agency) — Has established acceptable intake (AI) limits for nitrosamine impurities and required companies to update product specifications accordingly

  • ICH M7 — Provides the framework for assessment and control of DNA-reactive (mutagenic) impurities in pharmaceuticals

  • USP and EP — Pharmacopoeial standards provide traceability frameworks for reference standards used in nitrosamine testing

Non-compliance with nitrosamine impurity limits can result in product recalls, regulatory action, and most critically, patient safety risks. Having access to certified reference standards like those supplied by SynZeal's N-Nitroso Meglumine is the foundation of any compliant analytical programme.

Analytical Applications of N-Nitroso Meglumine Reference Standards

Pharmaceutical laboratories use certified N-Nitroso Meglumine reference standards in several critical analytical workflows:

1. Analytical Method Development

Developing a sensitive, selective analytical method for detecting trace N-Nitroso Meglumine in drug products requires a well-characterised reference standard. Laboratories typically employ RP-HPLC or LC-MS/MS methods, using the reference standard to optimise chromatographic conditions, mobile phase composition, and detector response.

2. Analytical Method Validation (AMV)

Regulatory submissions — whether for ANDA, NDA, or DMF filings — require validated analytical methods for nitrosamine impurities. Method validation parameters including specificity, linearity, limit of detection (LOD), limit of quantification (LOQ), accuracy, and precision all depend on access to a certified N-Nitroso Meglumine standard of known purity.

3. Quality Control (QC) Testing

During routine commercial manufacturing, QC laboratories test each batch of meglumine-containing products for nitrosamine impurity levels. The reference standard serves as the calibrant and system suitability standard in these routine analyses.

4. ANDA and NDA Regulatory Filing Support

Abbreviated New Drug Applications and New Drug Applications must now include nitrosamine risk assessments and, where applicable, validated test methods. Reference standards with appropriate characterisation data and regulatory-compliant Certificates of Analysis are essential for supporting these submissions.

5. Stability Studies

Understanding whether N-Nitroso Meglumine forms or increases during a product's shelf life is a critical element of stability programmes. Reference standards enable quantitative monitoring across stability timepoints.

SynZeal's N-Nitroso Meglumine: What Makes It the Right Choice?

SynZeal Research Pvt. Ltd. is an Ahmedabad, Gujarat-based manufacturer and supplier of pharmaceutical impurity standards and reference materials. Their N-Nitroso Meglumine standard is supplied with comprehensive characterization data designed to meet the needs of pharmaceutical laboratories worldwide.

Key features of SynZeal's N-Nitroso Meglumine supply include:

  • Detailed Characterization Data — IR, Mass spectrometry, HPLC/GC purity, NMR, TGA report, CMR, and DEPT analysis

  • Certified Certificate of Analysis (CoA) — Compliant with regulatory guidelines for pharmaceutical reference standards

  • Pharmacopoeial Traceability — Traceability against USP or EP standards provided based on feasibility

  • Regulatory Compliance — Supplied with characterization data compliant with ICH and FDA guidelines

  • Analytical Purpose Supply — Products are supplied for analytical use, supporting ANDA/DMF filing and commercial QC

SynZeal offers one of the most extensive ranges of nitrosamine-related impurity standards available from a single supplier — making them a practical, efficient choice for pharmaceutical companies managing multi-compound nitrosamine testing programmes.

N-Nitroso Meglumine and the Broader Nitrosamine Challenge in Pharma

The identification of nitrosamine impurities in pharmaceuticals represents one of the most significant quality challenges the industry has faced in recent decades. Since the discovery of NDMA contamination in valsartan in 2018, regulators globally have expanded their scrutiny to cover a wide range of drug substances and excipients — including meglumine.

For pharmaceutical manufacturers, the key takeaways are:

  1. Risk Assessment is Mandatory — Every product containing meglumine or meglumine-based salts must be assessed for the potential formation of N-Nitroso Meglumine

  2. Validated Methods are Required — Regulatory submissions must include validated analytical methods capable of detecting this impurity at trace levels

  3. Reference Standards Must Be Certified — Only certified reference standards with full characterization data are acceptable for regulatory submissions and QC testing

  4. Acceptable Intake Limits Apply — Finished products must meet the acceptable daily intake limits set by FDA and EMA for nitrosamine impurities

  5. Ongoing Monitoring is Necessary — Nitrosamine impurity levels must be monitored through the product lifecycle, including post-approval stability programmes

Frequently Asked Questions About N-Nitroso Meglumine

  1. What is the CAS number for N-Nitroso Meglumine? 

N-Nitroso Meglumine has CAS number 10356-92-0. Its molecular formula is C₇H₁₆N₂O₆ and molecular weight is 224.21 g/mol.

  1. Is N-Nitroso Meglumine safe for human use?

No. N-Nitroso Meglumine is classified as a potential human carcinogen and belongs to the nitrosamine impurity class. Reference standards supplied by companies like SynZeal are strictly for analytical laboratory purposes and are not intended for human administration.

  1. Which drug products require N-Nitroso Meglumine testing?

Any pharmaceutical product containing meglumine — including contrast agents (iopamidol, iomeprol), injectable formulations with meglumine salts, and drug substances using meglumine as a solubilizing agent — should be assessed and tested for this impurity.

  1. What analytical techniques are used to detect N-Nitroso Meglumine?

RP-HPLC and LC-MS/MS are the primary techniques used for detecting and quantifying N-Nitroso Meglumine in pharmaceutical matrices. Method development using certified reference standards is essential to achieve adequate sensitivity and selectivity at the trace levels required by regulatory guidelines.

  1. Where can I source a certified N-Nitroso Meglumine reference standard?

SynZeal Research Pvt. Ltd. supplies certified N-Nitroso Meglumine reference standards with full characterization data, certified CoA, and pharmacopoeial traceability. Their standards are used by major pharmaceutical companies globally for ANDA/DMF filing and commercial QC applications.

  1. What is the difference between N-Nitroso Meglumine and 14C-N-Nitroso Meglumine?

14C-N-Nitroso Meglumine is a radiolabelled isotopic variant of the standard compound, used in specialised metabolic and pharmacokinetic research studies. The standard N-Nitroso Meglumine (CAS 10356-92-0) is used for routine analytical method development, validation, and QC testing in pharmaceutical manufacturing.
Location: Ahmedabad, Gujarat, India

Comments

Post a Comment

Popular posts from this blog

The Crucial Role of Reference Standards in the Pharmaceutical Industry

Image
  Introduction In modern pharmaceutical research, accuracy isn’t optional—it’s essential. Every Active Pharmaceutical Ingredient (API) and every formulation depends on precise analytical testing. This is where reference standards play a critical role. These highly purified compounds serve as measurement benchmarks, ensuring that every analytical result is consistent, reliable, and compliant with global regulatory expectations. Among global providers, SynZeal Research has emerged as a trusted partner supplying high-quality impurity standards, reference standards, metabolites, and custom synthesis materials to support consistent analytical performance from R&D to regulatory submission. Why Reference Standards Matter in Pharma 1. Ensuring Accurate API Identification Pharmaceutical companies rely on reference standards to confirm the identity of APIs and impurities using techniques like HPLC, GC, LC-MS, NMR, and IR. A high-purity standard ensures that analytical teams can verify e...
Read more

Pharmaceutical Reference Standards: A Complete Guide by SynZeal

Image
  In modern pharmaceutical research and quality control, pharmaceutical reference standards are foundational tools that ensure accurate, consistent, and compliant analytical results. At SynZeal , we specialize in delivering high-purity reference materials — including APIs, impurity standards, metabolites, isotopically labelled compounds and custom reference standards — to support global drug development and regulatory testing workflows. What Are Pharmaceutical Reference Standards? A pharmaceutical reference standard is a well-characterized, highly purified material used as a benchmark for testing the identity, strength, quality, and purity of drug substances, excipients and finished products. These standards are essential in analytical method development, quality control testing, and regulatory submissions. Reference standards can be sourced from national or international pharmacopeias such as the United States Pharmacopeia (USP), European Pharmacopoeia (EP), or developed in-ho...
Read more

Pharmaceutical Reference Standards: Complete Guide to API Standards, Impurities & Analytical Testing

Image
What Are Pharmaceutical Reference Standards? A  pharmaceutical reference standard  is a highly characterized, authenticated chemical substance that serves as the basis for comparison in analytical testing. These materials establish identity, purity, potency, and overall quality of drug substances (APIs) and drug products during development, manufacturing, and regulatory submission. Regulatory agencies worldwide — including the US FDA, European Medicines Agency (EMA), and WHO — require that quality control (QC) laboratories use certified reference materials traceable to internationally recognized pharmacopoeias. Without them, no analytical method can be considered validated or its results defensible in a regulatory submission. Quick Answer:  Pharmaceutical reference standards are certified chemical substances used as a yardstick in analytical tests to confirm a drug's identity, purity, and potency — they are mandatory in all ICH-compliant quality control workflows. Types o...
Read more